By Fineline Cube 
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted the marketing application for its subsidiary’s semaglutide injection. The application is for the blood glucose control of adult patients with type 2 diabetes.
Drug Profile
Semaglutide injection is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. It is primarily used for blood glucose control in type 2 diabetes patients and long-term weight management in obesity or overweight patients.
Market Context
Developed by Novo Nordisk, semaglutide is currently the only product of its kind approved for marketing in China. However, competition is emerging as companies like Qilu Pharma, Jiuyuan Genetic, and Livzon Pharma have also submitted marketing applications for semaglutide in China, signaling a growing interest in this therapeutic area.-Fineline Info & Tech